Placental Cells for Diabetic Foot Ulcers
30. juni 2026 opdateret af: Wake Forest University Health Sciences
Phase 1 Safety Trial of Placental Stem Cells (PLSC) to Accelerate the Healing of Diabetic Foot Ulcers
The purpose of this research study is to test the safety of placental stem cells to treat non-healing diabetic foot ulcers.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a prospective, non-randomized, single institution, Phase 1 safety trial to evaluate the safety of placental stem cells and the rate of diabetic foot ulcer healing in a population of subjects with non-healing diabetic foot ulcers for at least 4 weeks.
The trial will also explore the clinical outcomes of placental stem cells treatment on diabetic peripheral neuropathy.
Furthermore, the trial will evaluate the effect of the placental stem cells on serum biomarkers associated with diabetic foot ulcers and diabetic peripheral neuropathy (measured pre- and post-treatment) and correlate the biomarker levels with any changes in diabetic foot ulcers and diabetic peripheral neuropathy.
Twelve adult subjects with non-healing diabetic foot ulcers for at least four weeks from diagnosis and not more than 12 months with wound sizes ≥ 2 cm2 and ≤ 4 cm2 will be recruited and treated.
Subjects will be followed for 12 months after treatment.
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
12
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Mary-Clare Day, RN
- Telefonnummer: 336-713-1343
- E-mail: maryclare.day@advocatehealth.org
Studiesteder
-
-
North Carolina
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Atrium Health Wake Forest Baptist
-
Kontakt:
- Mary-Clare Day, RN
- Telefonnummer: 336-713-1343
- E-mail: maryclare.day@advocatehealth.org
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Diagnosed with Type 2 Diabetes mellitus (DM) - for at least 1 year
- Unilateral non-healing Diabetic Foot Ulcer (DFU) > 2 cm2 and ≤ 4 cm2 (length × width) for at least four weeks despite Atrium Health Wake Forest Baptist standard of care treatment (which can include total contact cast, knee high air cast, and/or compression wrap)
- No new diabetes medication for at least 2 weeks pre-treatment
- Subjects must be willing to avoid steroids for the week prior to procedure day
Exclusion Criteria:
- Clinical signs of active infection requiring systemic antibiotic therapy less than 7 days prior to enrollment.
- Radiographic or clinical evidence of active and untreated osteomyelitis at the target ulcer site. Current use of systemic immunosuppressive therapy, including chronic corticosteroids (equivalent to >10 mg/day prednisone for >14 days).
- Hemoglobin (Hgb) A1C >12.0 at screening or time in range for the blood glucose level (TIR) less than 30%. Hb A1c should not be used for patient with hypoalbuminemia or anemia in the past 3 months and for patients with Chronic Kidney disease stage 4. For patients who have Continuous Glucose Monitor (CGM), instead of Hb A1c, TIR (time in range) less than 30 % will be used.
- Patients who are unable / unwilling to tolerate an effective offloading approach. This includes total contact cast, soft felted cast or knee high fracture boot.
- Current alcohol or substance abuse that, in the opinion of the investigators, would interfere with study participation.
- Active malignancy or malignancy related limb amputation.
- Women that are pregnant or planning to become pregnant during the study.
- Patients with albumin levels less than 3.5 or prealbumin levels less than 18.
- Subjects with any conditions that the clinical Investigator believes may jeopardize the safety of the patient to participate in the trial.
- Severe peripheral arterial disease (PAD) (Ankle-Brachial Index (ABI) less than 0.5) or TCOM (Transcutaneous Oximetry Measurement) less than 40 mmHg.
- TWSB > 30 cm2 (total wound surface burden)
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Diabetic with Foot Ulcer
Type 2 diabetes mellitus with a non-healing (> 4 weeks) unilateral diabetic foot ulcer despite standard of care treatment
|
Injection of 30 M placenta stem cells into/around the diabetic foot ulcer and along the anterior and posterior tibial arteries of the index leg.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Injection Sites Bleeding
Tidsramme: Month 1
|
Number of Injection Sites Bleeding
|
Month 1
|
|
Number of Injection Sites Bleeding
Tidsramme: Month 3
|
Number of Injection Sites Bleeding
|
Month 3
|
|
Number of Injection Sites Bleeding
Tidsramme: Month 6
|
Number of Injection Sites Bleeding
|
Month 6
|
|
Number of Injection Sites Bleeding
Tidsramme: Month 12
|
Number of Injection Sites Bleeding
|
Month 12
|
|
Number of Injection Sites infection/inflammation
Tidsramme: Month 1
|
Number of Injection Sites infection/inflammation
|
Month 1
|
|
Number of Injection Sites infection/inflammation
Tidsramme: Month 3
|
Number of Injection Sites infection/inflammation
|
Month 3
|
|
Number of Injection Sites infection/inflammation
Tidsramme: Month 6
|
Number of Injection Sites infection/inflammation
|
Month 6
|
|
Number of Injection Sites infection/inflammation
Tidsramme: Month 12
|
Number of Injection Sites infection/inflammation
|
Month 12
|
|
Number of Injection Sites with damage to surrounding tissue
Tidsramme: Month 1
|
Number of Injection Sites with damage to surrounding tissue
|
Month 1
|
|
Number of Injection Sites with damage to surrounding tissue
Tidsramme: Month 3
|
Number of Injection Sites with damage to surrounding tissue
|
Month 3
|
|
Number of Injection Sites with damage to surrounding tissue
Tidsramme: Month 6
|
Number of Injection Sites with damage to surrounding tissue
|
Month 6
|
|
Number of Injection Sites with damage to surrounding tissue
Tidsramme: Month 12
|
Number of Injection Sites with damage to surrounding tissue
|
Month 12
|
|
Number of Subjects with pain
Tidsramme: Month 1
|
Number of Subjects with pain
|
Month 1
|
|
Number of Subjects with pain
Tidsramme: Month 3
|
Number of Subjects with pain
|
Month 3
|
|
Number of Subjects with pain
Tidsramme: Month 6
|
Number of Subjects with pain
|
Month 6
|
|
Number of Subjects with pain
Tidsramme: Month 12
|
Number of Subjects with pain
|
Month 12
|
|
Number of Subjects with allergic reaction to placental cells
Tidsramme: Month 1
|
Number of Subjects with allergic reaction to placental cells
|
Month 1
|
|
Number of Subjects with allergic reaction to placental cells
Tidsramme: Month 3
|
Number of Subjects with allergic reaction to placental cells
|
Month 3
|
|
Number of Subjects with allergic reaction to placental cells
Tidsramme: Month 6
|
Number of Subjects with allergic reaction to placental cells
|
Month 6
|
|
Number of Subjects with allergic reaction to placental cells
Tidsramme: Month 12
|
Number of Subjects with allergic reaction to placental cells
|
Month 12
|
|
Number of Subjects with worsening of wound
Tidsramme: Month 1
|
Number of Subjects with worsening of wound
|
Month 1
|
|
Number of Subjects with worsening of wound
Tidsramme: Month 3
|
Number of Subjects with worsening of wound
|
Month 3
|
|
Number of Subjects with worsening of wound
Tidsramme: Month 6
|
Number of Subjects with worsening of wound
|
Month 6
|
|
Number of Subjects with worsening of wound
Tidsramme: Month 12
|
Number of Subjects with worsening of wound
|
Month 12
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Diabetic Foot Ulcer (DFU) size
Tidsramme: Month 12
|
DFU healing in this trial will be assessed by measuring the size of the DFU and plotting open wound size over the 12-month follow-up period.
|
Month 12
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Diabetic Peripheral Neuropathy - Semmes-Weinstein Monofilament and Vibration Test
Tidsramme: Months 1, 3, 6 and 12
|
The Semmes-Weinstein Monofilament Test is a diagnostic tool used to assess cutaneous touch and pressure sensation.
By using calibrated nylon strands that buckle at specific forces, clinicians can evaluate peripheral nerve function and reliably detect the loss of protective sensation, primarily caused by conditions like diabetic neuropathy
|
Months 1, 3, 6 and 12
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Lucian G. Vlad, MD, Atrium Health Wake Forest Baptist
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
1. oktober 2026
Primær færdiggørelse (Anslået)
1. december 2028
Studieafslutning (Anslået)
1. december 2028
Datoer for studieregistrering
Først indsendt
30. juni 2026
Først indsendt, der opfyldte QC-kriterier
30. juni 2026
Først opslået (Faktiske)
7. juli 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
7. juli 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
30. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IRB00152562
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ja
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .